Key facts
- This page summarizes Robert E. Hoffman's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2026, 16:23.
Robert E. Hoffman - 28 May 2026 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Director
- Issuer ticker
- ESPR
- Reported as of
- 28 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2026, 16:23:36 UTC
- Prior SEC filing
- 24 Mar 2026
- Next SEC filing
- 23 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sheldon L. Koenig, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Hoffman filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 01 Jun 2026.
Change
- Previous filing in this sequence was filed on 24 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001166288
Primary reporting owner
Hoffman Robert E.
- Relationship
- Director
- Address
- C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR
- Signature
- /s/ Sheldon L. Koenig, by power of attorney
- Signature date
- 01 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ESPR
transaction
Common Stock
Award
- Transaction value
- Shares
- +79,873
- Change %
- +1513%
- Price
- $0.000000*
- Shares after
- 85,153
- Date
- 28 May 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.